Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AsterA: Asciminib and TKIs for Treatment-free Remission in CML
NCT06368414Phase 2Recruiting
- Sponsor
- The Korean Society of Hematology
- Start
- Mar 2024
- Primary completion
- Aug 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of asciminib in chronic myeloid leukemia (CML), sponsored by The Korean Society of Hematology. Started Mar 2024; status: recruiting.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT06368414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06368414.